View Financial HealthSofina Société Anonyme 配当と自社株買い配当金 基準チェック /26Sofina Société Anonyme配当を支払う会社であり、現在の利回りは1.64%です。主要情報1.6%配当利回り-6.7%バイバック利回り総株主利回り-5.0%将来の配当利回り1.8%配当成長4.0%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向109%最近の配当と自社株買いの更新お知らせ • 50mSofina Société Anonyme announces Annual dividend, payable on May 29, 2026Sofina Société Anonyme announced Annual dividend of EUR 2.5620 per share payable on May 29, 2026, ex-date on May 27, 2026 and record date on May 28, 2026.Upcoming Dividend • May 13Upcoming dividend of €2.45 per shareEligible shareholders must have bought the stock before 20 May 2025. Payment date: 22 May 2025. Payout ratio is a comfortable 8.6% but the company is paying out more than the cash it is generating. Trailing yield: 1.4%. Lower than top quartile of Belgian dividend payers (6.7%). Lower than average of industry peers (2.8%).Upcoming Dividend • May 05Upcoming dividend of €2.27 per share at 1.6% yieldEligible shareholders must have bought the stock before 12 May 2023. Payment date: 16 May 2023. The company is not currently making a profit but it is cash flow positive. Trailing yield: 1.6%. Lower than top quartile of Belgian dividend payers (6.4%). Lower than average of industry peers (2.6%).Upcoming Dividend • May 06Upcoming dividend of €2.19 per shareEligible shareholders must have bought the stock before 13 May 2022. Payment date: 17 May 2022. Payout ratio is a comfortable 4.1% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of Belgian dividend payers (5.7%). Lower than average of industry peers (2.6%).すべての更新を表示Recent updatesお知らせ • 50mSofina Société Anonyme announces Annual dividend, payable on May 29, 2026Sofina Société Anonyme announced Annual dividend of EUR 2.5620 per share payable on May 29, 2026, ex-date on May 27, 2026 and record date on May 28, 2026.お知らせ • Apr 11Sofina Société Anonyme, Annual General Meeting, May 13, 2026Sofina Société Anonyme, Annual General Meeting, May 13, 2026, at 15:00 Romance Standard Time.New Risk • Mar 29New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 58% Last year net profit margin: 95% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 30% per year over the past 5 years. Minor Risk Profit margins are more than 30% lower than last year (58% net profit margin).お知らせ • Mar 24Sofina Société Anonyme to Report Fiscal Year 2026 Results on Mar 24, 2027Sofina Société Anonyme announced that they will report fiscal year 2026 results on Mar 24, 2027New Risk • Mar 23New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).新しいナラティブ • Feb 04Why I invest in Sofina (Dividend growth)NAV As Sofina is an investment holding company, NAV is an important factor in my evaluation. This Net Asset Value is estimated at a price share of 297 Eur, up from 294 last year.分析記事 • Jan 02Getting In Cheap On Sofina Société Anonyme (EBR:SOF) Is UnlikelyWhen close to half the companies in Belgium have price-to-earnings ratios (or "P/E's") below 15x, you may consider...お知らせ • Oct 30Terumo Corporation (TSE:4543) completed the acquisition of remaining 99.5% stake in OrganOx Limited from a group of shareholders.Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire remaining 99.5% stake in OrganOx Limited from a group of shareholders for $1.5 billion on August 23, 2025. Upon completion of the transaction, OrganOx will become a wholly owned subsidiary of Terumo. The transaction will be funded from cash on hand and borrowings. For the period ending December 31, 2024, OrganOx Limited reported total revenue of $69.14 million and EBIT of $9.01 million. As of December 31, 2024, OrganOx Limited reported total assets of $96.9 million and total common equity of $71.56 million. The transaction is subject to approval by regulatory board / committee. The transaction is expected to close in FY2025. Perella Weinberg Partners and Piper Sandler served as OrganOx’s financial advisors and Robbie McLaren, Ross McAloon, Charles Ruck, Elizabeth Richards, Betty Pang, Chad Jennings, Sean Finn, Maj Vaseghi, Kendall Burnett, Hector Armengod, Patrick English, Catherine Hein and Philipp Studt of Latham & Watkins acted as legal counsel to OrganOx in this transaction. Terumo Corporation (TSE:4543) completed the acquisition of remaining 99.5% stake in OrganOx Limited from a group of shareholders on October 29, 2025.分析記事 • Sep 07Some Shareholders Feeling Restless Over Sofina Société Anonyme's (EBR:SOF) P/E RatioSofina Société Anonyme's ( EBR:SOF ) price-to-earnings (or "P/E") ratio of 20.2x might make it look like a sell right...お知らせ • Sep 04Sofina Société Anonyme to Report First Half, 2026 Results on Sep 03, 2026Sofina Société Anonyme announced that they will report first half, 2026 results on Sep 03, 2026お知らせ • Aug 25Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire 99.5% stake in OrganOx Limited from a group of shareholders in a transaction valued at $1.5 billion.Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire 99.5% stake in OrganOx Limited from a group of shareholders in a transaction valued at $1.5 billion on August 23, 2025. Upon completion of the transaction, OrganOx will become a wholly owned subsidiary of Terumo. For the period ending December 31, 2024, OrganOx Limited reported total revenue of $69.14 million and EBIT of $9.01 million. As of December 31, 2024, OrganOx Limited reported total assets of $96.9 million and total common equity of $71.56 million. The transaction is subject to approval by regulatory board / committee. Perella Weinberg Partners and Piper Sandler served as OrganOx’s financial advisors and Latham & Watkins acted as legal counsel to OrganOx in this transaction.Upcoming Dividend • May 13Upcoming dividend of €2.45 per shareEligible shareholders must have bought the stock before 20 May 2025. Payment date: 22 May 2025. Payout ratio is a comfortable 8.6% but the company is paying out more than the cash it is generating. Trailing yield: 1.4%. Lower than top quartile of Belgian dividend payers (6.7%). Lower than average of industry peers (2.8%).お知らせ • Apr 25Proeduca Summa, S.L., Renta Genova, S.L., Asua Inversiones, S.L., Portobello Capital Gestión, SGEIC, S.A. and Sofina Société Anonyme (ENXTBR:SOF) proposed to acquire 7.09% stake in Proeduca Altus, S.A. (BME:PRO) for approximately €110 million.Proeduca Summa, S.L., Renta Genova, S.L., Asua Inversiones, S.L., Portobello Capital Gestión, SGEIC, S.A. and Sofina Société Anonyme (ENXTBR:SOF) proposed to acquire 7.09% stake in Proeduca Altus, S.A. (BME:PRO) for approximately €110 million on April 24, 2025. A cash consideration valued at €34.01 per share will be paid by Proeduca Summa, S.L., Renta Genova, S.L., Asua Inversiones, S.L., Portobello Capital Gestión, SGEIC, S.A. and Sofina Société Anonyme. As part of consideration, an undisclosed value is paid towards common equity of Proeduca Altus, S.A. The proposed price for the offer is €34.01 per share, valuing the Proeduca Altus at approximately €1.536 billion. The transaction is subject to Proeduca Altus shareholders approval. Ernst & Young Transaction Advisory Services España acted as fairness opinion provider to Proeduca Altus, S.A.お知らせ • Mar 27Sofina Société Anonyme to Report Fiscal Year 2025 Final Results on Mar 26, 2026Sofina Société Anonyme announced that they will report fiscal year 2025 final results on Mar 26, 2026New Risk • Mar 24New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 35% per year over the past 5 years. Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).Price Target Changed • Jul 11Price target decreased by 14% to €292Down from €341, the current price target is an average from 3 analysts. New target price is 36% above last closing price of €214. Stock is up 9.3% over the past year. The company posted a net loss per share of €3.12 last year.お知らせ • Apr 04Sofina Société Anonyme, Annual General Meeting, May 08, 2025Sofina Société Anonyme, Annual General Meeting, May 08, 2025.お知らせ • Mar 29Sofina Société Anonyme to Report Fiscal Year 2024 Results on Mar 26, 2025Sofina Société Anonyme announced that they will report fiscal year 2024 results on Mar 26, 2025New Risk • Mar 24New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 22% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).お知らせ • Jan 23Sofina Société Anonyme to Report First Half, 2024 Results on Sep 05, 2024Sofina Société Anonyme announced that they will report first half, 2024 results on Sep 05, 2024お知らせ • Dec 20Proofpoint, Inc. acquire Tessian Limited.Proofpoint, Inc. entered into a definitive agreement to acquire Tessian Limited on October 30, 2023. Tessian’s solutions are expected to become part of Proofpoint’s offering upon the closing of the acquisition. The acquisition is expected to close in late 2023 to early 2024, subject to customary closing conditions, including any required regulatory approvals. Piper Sandler Ltd. acted as financial advisor to Tessian Limited. Vincent Bergin, Peter Stach, P.C., Andrew Struckmeyer, David Higgins, Corey D. Fox, P.C., Bradley C. Reed, P.C., John Patten, Peter Abbott, Matthew Sinclair-Thomson, Kirsteen Nicol, Katherine C. Nemeth, Michael Falk, P.C., Sydney Jones and Jackson Phinney of Kirkland & Ellis International LLP and Kirkland & Ellis LLP acted as legal advisor to Proofpoint. The transaction is closed on December 19, 2023.Proofpoint, Inc. completed the acquisition of Tessian Limited on December 19, 2023.Upcoming Dividend • May 05Upcoming dividend of €2.27 per share at 1.6% yieldEligible shareholders must have bought the stock before 12 May 2023. Payment date: 16 May 2023. The company is not currently making a profit but it is cash flow positive. Trailing yield: 1.6%. Lower than top quartile of Belgian dividend payers (6.4%). Lower than average of industry peers (2.6%).Price Target Changed • Nov 16Price target decreased to €367Down from €415, the current price target is an average from 2 analysts. New target price is 66% above last closing price of €221. Stock is down 45% over the past year. The company posted earnings per share of €76.99 last year.Price Target Changed • Jun 01Price target decreased to €367Down from €420, the current price target is provided by 1 analyst. New target price is 69% above last closing price of €217. Stock is down 37% over the past year. The company posted earnings per share of €76.99 last year.Valuation Update With 7 Day Price Move • May 24Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to €234, the stock trades at a trailing P/E ratio of 3x. Average trailing P/E is 9x in the Diversified Financial industry in Europe. Total returns to shareholders of 35% over the past three years.Upcoming Dividend • May 06Upcoming dividend of €2.19 per shareEligible shareholders must have bought the stock before 13 May 2022. Payment date: 17 May 2022. Payout ratio is a comfortable 4.1% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of Belgian dividend payers (5.7%). Lower than average of industry peers (2.6%).Price Target Changed • Jul 24Price target increased to €348Up from €310, the current price target is provided by 1 analyst. New target price is 12% below last closing price of €396. Stock is up 70% over the past year.Price Target Changed • Mar 22Price target increased to €310Up from €283, the current price target is provided by 1 analyst. New target price is 6.7% above last closing price of €291. Stock is up 74% over the past year.Is New 90 Day High Low • Feb 03New 90-day high: €286The company is up 22% from its price of €235 on 04 November 2020. The Belgian market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Diversified Financial industry, which is up 17% over the same period.Is New 90 Day High Low • Dec 29New 90-day high: €275The company is up 18% from its price of €233 on 30 September 2020. The Belgian market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Diversified Financial industry, which is up 12% over the same period.Is New 90 Day High Low • Nov 17New 90-day high: €260The company is up 7.0% from its price of €243 on 19 August 2020. The Belgian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Diversified Financial industry, which is up 5.0% over the same period.Is New 90 Day High Low • Oct 29New 90-day low: €223The company is down 4.0% from its price of €234 on 30 July 2020. The Belgian market is down 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Diversified Financial industry, which is down 6.0% over the same period.決済の安定と成長配当データの取得安定した配当: SOFの1株当たり配当金は過去10年間安定しています。増加する配当: SOFの配当金は過去10年間にわたって増加しています。配当利回り対市場Sofina Société Anonyme 配当利回り対市場SOF 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (SOF)1.6%市場下位25% (BE)2.4%市場トップ25% (BE)6.5%業界平均 (Diversified Financial)4.3%アナリスト予想 (SOF) (最長3年)1.8%注目すべき配当: SOFの配当金 ( 1.64% ) はBelgian市場の配当金支払者の下位 25% ( 2.35% ) と比べると目立ったものではありません。高配当: SOFの配当金 ( 1.64% ) はBelgian市場の配当金支払者の上位 25% ( 6.53% ) と比較すると低いです。株主への利益配当収益カバレッジ: SOFは高い 配当性向 ( 109.3% ) のため、配当金の支払いは利益によって十分にカバーされていません。株主配当金キャッシュフローカバレッジ: SOFは配当金を支払っていますが、同社にはフリーキャッシュフローがありません。高配当企業の発掘7D1Y7D1Y7D1YBE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 00:49終値2026/05/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sofina Société Anonyme 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Marc DebrouwerDegroof Petercam
お知らせ • 50mSofina Société Anonyme announces Annual dividend, payable on May 29, 2026Sofina Société Anonyme announced Annual dividend of EUR 2.5620 per share payable on May 29, 2026, ex-date on May 27, 2026 and record date on May 28, 2026.
Upcoming Dividend • May 13Upcoming dividend of €2.45 per shareEligible shareholders must have bought the stock before 20 May 2025. Payment date: 22 May 2025. Payout ratio is a comfortable 8.6% but the company is paying out more than the cash it is generating. Trailing yield: 1.4%. Lower than top quartile of Belgian dividend payers (6.7%). Lower than average of industry peers (2.8%).
Upcoming Dividend • May 05Upcoming dividend of €2.27 per share at 1.6% yieldEligible shareholders must have bought the stock before 12 May 2023. Payment date: 16 May 2023. The company is not currently making a profit but it is cash flow positive. Trailing yield: 1.6%. Lower than top quartile of Belgian dividend payers (6.4%). Lower than average of industry peers (2.6%).
Upcoming Dividend • May 06Upcoming dividend of €2.19 per shareEligible shareholders must have bought the stock before 13 May 2022. Payment date: 17 May 2022. Payout ratio is a comfortable 4.1% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of Belgian dividend payers (5.7%). Lower than average of industry peers (2.6%).
お知らせ • 50mSofina Société Anonyme announces Annual dividend, payable on May 29, 2026Sofina Société Anonyme announced Annual dividend of EUR 2.5620 per share payable on May 29, 2026, ex-date on May 27, 2026 and record date on May 28, 2026.
お知らせ • Apr 11Sofina Société Anonyme, Annual General Meeting, May 13, 2026Sofina Société Anonyme, Annual General Meeting, May 13, 2026, at 15:00 Romance Standard Time.
New Risk • Mar 29New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 58% Last year net profit margin: 95% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 30% per year over the past 5 years. Minor Risk Profit margins are more than 30% lower than last year (58% net profit margin).
お知らせ • Mar 24Sofina Société Anonyme to Report Fiscal Year 2026 Results on Mar 24, 2027Sofina Société Anonyme announced that they will report fiscal year 2026 results on Mar 24, 2027
New Risk • Mar 23New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).
新しいナラティブ • Feb 04Why I invest in Sofina (Dividend growth)NAV As Sofina is an investment holding company, NAV is an important factor in my evaluation. This Net Asset Value is estimated at a price share of 297 Eur, up from 294 last year.
分析記事 • Jan 02Getting In Cheap On Sofina Société Anonyme (EBR:SOF) Is UnlikelyWhen close to half the companies in Belgium have price-to-earnings ratios (or "P/E's") below 15x, you may consider...
お知らせ • Oct 30Terumo Corporation (TSE:4543) completed the acquisition of remaining 99.5% stake in OrganOx Limited from a group of shareholders.Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire remaining 99.5% stake in OrganOx Limited from a group of shareholders for $1.5 billion on August 23, 2025. Upon completion of the transaction, OrganOx will become a wholly owned subsidiary of Terumo. The transaction will be funded from cash on hand and borrowings. For the period ending December 31, 2024, OrganOx Limited reported total revenue of $69.14 million and EBIT of $9.01 million. As of December 31, 2024, OrganOx Limited reported total assets of $96.9 million and total common equity of $71.56 million. The transaction is subject to approval by regulatory board / committee. The transaction is expected to close in FY2025. Perella Weinberg Partners and Piper Sandler served as OrganOx’s financial advisors and Robbie McLaren, Ross McAloon, Charles Ruck, Elizabeth Richards, Betty Pang, Chad Jennings, Sean Finn, Maj Vaseghi, Kendall Burnett, Hector Armengod, Patrick English, Catherine Hein and Philipp Studt of Latham & Watkins acted as legal counsel to OrganOx in this transaction. Terumo Corporation (TSE:4543) completed the acquisition of remaining 99.5% stake in OrganOx Limited from a group of shareholders on October 29, 2025.
分析記事 • Sep 07Some Shareholders Feeling Restless Over Sofina Société Anonyme's (EBR:SOF) P/E RatioSofina Société Anonyme's ( EBR:SOF ) price-to-earnings (or "P/E") ratio of 20.2x might make it look like a sell right...
お知らせ • Sep 04Sofina Société Anonyme to Report First Half, 2026 Results on Sep 03, 2026Sofina Société Anonyme announced that they will report first half, 2026 results on Sep 03, 2026
お知らせ • Aug 25Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire 99.5% stake in OrganOx Limited from a group of shareholders in a transaction valued at $1.5 billion.Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire 99.5% stake in OrganOx Limited from a group of shareholders in a transaction valued at $1.5 billion on August 23, 2025. Upon completion of the transaction, OrganOx will become a wholly owned subsidiary of Terumo. For the period ending December 31, 2024, OrganOx Limited reported total revenue of $69.14 million and EBIT of $9.01 million. As of December 31, 2024, OrganOx Limited reported total assets of $96.9 million and total common equity of $71.56 million. The transaction is subject to approval by regulatory board / committee. Perella Weinberg Partners and Piper Sandler served as OrganOx’s financial advisors and Latham & Watkins acted as legal counsel to OrganOx in this transaction.
Upcoming Dividend • May 13Upcoming dividend of €2.45 per shareEligible shareholders must have bought the stock before 20 May 2025. Payment date: 22 May 2025. Payout ratio is a comfortable 8.6% but the company is paying out more than the cash it is generating. Trailing yield: 1.4%. Lower than top quartile of Belgian dividend payers (6.7%). Lower than average of industry peers (2.8%).
お知らせ • Apr 25Proeduca Summa, S.L., Renta Genova, S.L., Asua Inversiones, S.L., Portobello Capital Gestión, SGEIC, S.A. and Sofina Société Anonyme (ENXTBR:SOF) proposed to acquire 7.09% stake in Proeduca Altus, S.A. (BME:PRO) for approximately €110 million.Proeduca Summa, S.L., Renta Genova, S.L., Asua Inversiones, S.L., Portobello Capital Gestión, SGEIC, S.A. and Sofina Société Anonyme (ENXTBR:SOF) proposed to acquire 7.09% stake in Proeduca Altus, S.A. (BME:PRO) for approximately €110 million on April 24, 2025. A cash consideration valued at €34.01 per share will be paid by Proeduca Summa, S.L., Renta Genova, S.L., Asua Inversiones, S.L., Portobello Capital Gestión, SGEIC, S.A. and Sofina Société Anonyme. As part of consideration, an undisclosed value is paid towards common equity of Proeduca Altus, S.A. The proposed price for the offer is €34.01 per share, valuing the Proeduca Altus at approximately €1.536 billion. The transaction is subject to Proeduca Altus shareholders approval. Ernst & Young Transaction Advisory Services España acted as fairness opinion provider to Proeduca Altus, S.A.
お知らせ • Mar 27Sofina Société Anonyme to Report Fiscal Year 2025 Final Results on Mar 26, 2026Sofina Société Anonyme announced that they will report fiscal year 2025 final results on Mar 26, 2026
New Risk • Mar 24New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 35% per year over the past 5 years. Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).
Price Target Changed • Jul 11Price target decreased by 14% to €292Down from €341, the current price target is an average from 3 analysts. New target price is 36% above last closing price of €214. Stock is up 9.3% over the past year. The company posted a net loss per share of €3.12 last year.
お知らせ • Apr 04Sofina Société Anonyme, Annual General Meeting, May 08, 2025Sofina Société Anonyme, Annual General Meeting, May 08, 2025.
お知らせ • Mar 29Sofina Société Anonyme to Report Fiscal Year 2024 Results on Mar 26, 2025Sofina Société Anonyme announced that they will report fiscal year 2024 results on Mar 26, 2025
New Risk • Mar 24New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 22% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).
お知らせ • Jan 23Sofina Société Anonyme to Report First Half, 2024 Results on Sep 05, 2024Sofina Société Anonyme announced that they will report first half, 2024 results on Sep 05, 2024
お知らせ • Dec 20Proofpoint, Inc. acquire Tessian Limited.Proofpoint, Inc. entered into a definitive agreement to acquire Tessian Limited on October 30, 2023. Tessian’s solutions are expected to become part of Proofpoint’s offering upon the closing of the acquisition. The acquisition is expected to close in late 2023 to early 2024, subject to customary closing conditions, including any required regulatory approvals. Piper Sandler Ltd. acted as financial advisor to Tessian Limited. Vincent Bergin, Peter Stach, P.C., Andrew Struckmeyer, David Higgins, Corey D. Fox, P.C., Bradley C. Reed, P.C., John Patten, Peter Abbott, Matthew Sinclair-Thomson, Kirsteen Nicol, Katherine C. Nemeth, Michael Falk, P.C., Sydney Jones and Jackson Phinney of Kirkland & Ellis International LLP and Kirkland & Ellis LLP acted as legal advisor to Proofpoint. The transaction is closed on December 19, 2023.Proofpoint, Inc. completed the acquisition of Tessian Limited on December 19, 2023.
Upcoming Dividend • May 05Upcoming dividend of €2.27 per share at 1.6% yieldEligible shareholders must have bought the stock before 12 May 2023. Payment date: 16 May 2023. The company is not currently making a profit but it is cash flow positive. Trailing yield: 1.6%. Lower than top quartile of Belgian dividend payers (6.4%). Lower than average of industry peers (2.6%).
Price Target Changed • Nov 16Price target decreased to €367Down from €415, the current price target is an average from 2 analysts. New target price is 66% above last closing price of €221. Stock is down 45% over the past year. The company posted earnings per share of €76.99 last year.
Price Target Changed • Jun 01Price target decreased to €367Down from €420, the current price target is provided by 1 analyst. New target price is 69% above last closing price of €217. Stock is down 37% over the past year. The company posted earnings per share of €76.99 last year.
Valuation Update With 7 Day Price Move • May 24Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to €234, the stock trades at a trailing P/E ratio of 3x. Average trailing P/E is 9x in the Diversified Financial industry in Europe. Total returns to shareholders of 35% over the past three years.
Upcoming Dividend • May 06Upcoming dividend of €2.19 per shareEligible shareholders must have bought the stock before 13 May 2022. Payment date: 17 May 2022. Payout ratio is a comfortable 4.1% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of Belgian dividend payers (5.7%). Lower than average of industry peers (2.6%).
Price Target Changed • Jul 24Price target increased to €348Up from €310, the current price target is provided by 1 analyst. New target price is 12% below last closing price of €396. Stock is up 70% over the past year.
Price Target Changed • Mar 22Price target increased to €310Up from €283, the current price target is provided by 1 analyst. New target price is 6.7% above last closing price of €291. Stock is up 74% over the past year.
Is New 90 Day High Low • Feb 03New 90-day high: €286The company is up 22% from its price of €235 on 04 November 2020. The Belgian market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Diversified Financial industry, which is up 17% over the same period.
Is New 90 Day High Low • Dec 29New 90-day high: €275The company is up 18% from its price of €233 on 30 September 2020. The Belgian market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Diversified Financial industry, which is up 12% over the same period.
Is New 90 Day High Low • Nov 17New 90-day high: €260The company is up 7.0% from its price of €243 on 19 August 2020. The Belgian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Diversified Financial industry, which is up 5.0% over the same period.
Is New 90 Day High Low • Oct 29New 90-day low: €223The company is down 4.0% from its price of €234 on 30 July 2020. The Belgian market is down 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Diversified Financial industry, which is down 6.0% over the same period.
